References
- Koleva-Kolarova RG, Oktora MP, Robijn AL, et al. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2017;55:16–25.
- Stanculeanu DL, Daniela Z, Lazescu A, et al. Development of new immunotherapy treatments in different cancer types. J Med Life. 2016;9(3):240–248.
- Drake CG, Jaffee E, Pardoll DM, et al. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81.
- Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489.
- Cohen D. Cancer drugs: high price, uncertain value. BMJ. 2017;359:j4543.
- IQVIA institute for human data science. [Internet] [Global oncology trends 2018]; 2018 [cited 2020 Nov 14]. Available from: https://www.iqvia.com/institute/reports/global-oncology-trends-2018.
- Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017;15(1):134.
- Paoletti X, Lewsley LA, Daniele G, et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Network Open. 2020;3(1):e1918939. .
- Godman B, Bucsics A, Vella Bonanno P, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
- Adams KT. Cancer immunotherapies–and their cost–take center stage at ASCO’s 2015 annual meeting. Managed Care (Langhorne, Pa). 2015;24(7):30–32.
- Tartari F, Santoni M, Burattini L, et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. Cancer Treat Rev. 2016;48:20–24.
- World health organization. [Internet] Pricing of cancer medicines and its impacts; 2018 [Cited 2020 Jan 6]. Available from: https://www.who.int/medicines/areas/access/report-on-the-pricing-of-cancer-medicines.pdf?ua=1.
- Ministry of health and welfare of Korea. [Internet] [Policy measures to optimize drug expenditure; 2006 [cited 2020 Jan 6]. Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&CONT_SEQ=39921
- Park SE, Lim SH, Choi HW, et al. Evaluation on the first 2 years of the positive list system in South Korea. Health Policy. 2012;104(1):32–39. .
- Bae EY, Lee EK. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. Value Health. 2009;12(Suppl 3):S36–41.
- Bae EY, Hong JM, Kwon HY, et al., Eight-year experience of using HTA in drug reimbursement: south Korea. Health Policy. 2016;120(6):612–620. .
- Ministry of health and welfare of Korea. [Internet] [Regulation introduction of risk sharing agreement 2013] [cited 2020 Jan 6]. Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PARMENU_ID=04&MENU_ID=0403&CONT_SEQ=290962&page=1
- Ministry of health and welfare of Korea. [Internet] [Regulation introduction of pharmacoeconomics evaluation exemption 2014] [cited 2020 Jan 6]. Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=315539&page=1.
- Kim S, Cho H, Kim J, et al. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways. Expert Rev Pharmacoecon Outcomes Res. Published online: 26 April 2020.
- Zampirolli Dias C, Godman B, Gargano LP, et al. Integrative Review of Managed Entry Agreements: chances and Limitations. Pharmacoeconomics. 2020;38(11):1165–1185.
- Kwon HY, Kim H, Godman B. Availability and affordability of drugs with a conditional approval by the european medicines agency; comparison of Korea with other countries and the implications. Front Pharmacol. 2018;9:938.
- Kim E-S, Kim J-A, Lee E-K. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007–2016 in South Korea. Expert Rev Pharmacoecon Outcomes Res. 2017;17(4):401–409. .
- Cacace M, Ettelt S, Mays N, et al. Assessing quality in cross-country comparisons of health systems and policies: towards a set of generic quality criteria. Health Policy. 2013;112(1–2):156–162. .
- Health insurance review and assessment service of Korea. [Internet] [Overview of NHI system]; 2020 [cited 2020 Nov 14]. Available from: https://www.hira.or.kr/dummy.do?pgmid=HIRAJ010000006002.
- Health insurance review and assessment service of Korea. [Internet] [Regulations on evaluation criteria and procedures for eligibility of drugs on reimbursement]; 2019 [cited 2020 Jul 7]. Available from: http://www.alio.go.kr/popSusiView21110.do?seq=2016110301311933.
- Health insurance review and assessment service of Korea. [Internet] [Detail evaluation criteria for new drugs to be negotiated]; 2020 [cited 2020 Jul 7]. Available from: https://biz.hira.or.kr/index.do?sso=ok.
- Ferrario A, Arāja D, Bochenek T, et al. The implementation of managed entry agreements in central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017;35(12):1271–1285. .
- Ministry of health and welfare of Korea. [Internet] [Drug price revaluation and national health insurance price cut]; 2002 [cited 2020 Jul 7]. Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=23369&page=703.
- Health insurance review and assessment service of Korea. [Internet] [Improvement measures for reference standards for foreign drug prices]; 2019 [cited 2020 Jul 8]. Available from: http://www.alio.go.kr/popSusiViewB1260.do.
- Health Insurance Review and Assessment Service of Korea. [Internet] [Result of drug reimbursement evaluation committee]; 2020 [cited 2020 Sep 6]. Available from: http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014040000.
- Schober P, Boer C, Schwarte L. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126:1.
- pan-Canadian Oncology Drug Review (Canada). [Internet] Keytruda review report; 2020 [cited 2020 8 Jul]. Available from: https://cadth.ca/keytruda-advanced-non-small-cell-lung-carcinoma-first-line-details
- National Institute for Health and Care Excellence (UK). [Internet] Pembrolizumab NICE technology appraisal guidance; 2018 [cited 2020 Jul 8]. Available from: https://www.nice.org.uk/guidance/ta531.
- OECD. [Internet] Addressing challenges in access to oncology medicines; 2020 [cited 2020 Jul 27]. Available from: https://www.oecd.org/health/health-systems/addressing-challenges-in-access-to-oncology-medicines.htm.
- Pauwels K, Huys I, Vogler S, et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8:171.
- Tay-Teo K, Ilbawi A, Hill SR. Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies. JAMA Network Open. 2019;2(1):e186875–e.
- Moreno SG, Epstein D. The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. J Mark Access Health Policy. 2019;7(1):1583536.
- Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology. 2013;27(2):80–1, 149.
- Zafar SY, Abernethy AP. Financial toxicity, Part II: how can we help with the burden of treatment-related costs? Oncology. 2013;27(4):253–4, 6.
- Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980–986. .
- Shankaran V, Ramsey S. Addressing the financial burden of cancer treatment: from copay to can’t pay. JAMA Oncol. 2015;1(3):273–274.
- The high price of progress. Nat Rev Clin Oncol. 2017;14(3):129.
- Holtorf AP, Gialama F, Wijaya KE, et al. External reference pricing for pharmaceuticals-a survey and literature review to describe best practices for countries with expanding healthcare coverage. Value Health Reg Issues. 2019;19:122–131.
- Piatkiewicz TJ, Traulsen JM, Risk-Sharing H-LT. Agreements in the EU: a systematic review of major trends. Pharmacoecon Open. 2018;2(2):109–123.
- Pauwels K, Huys I, Casteels M, et al. Market access of cancer drugs in European countries: improving resource allocation. Target Oncol. 2014;9(2):95–110.
- Wilson A, Cohen J. Patient access to new cancer drugs in the United States and Australia. Value Health. 2011;14(6):944–952.
- Mattingly TJ 2nd, Levy JF, Slejko JF, et al. Estimating drug costs: how do manufacturer net prices compare with other common US price references? Pharmacoecon Open. 2018;36(9):1093–1099.
- Shi L, Hodges M, Drummond M, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR drug cost task force report–part VI. Value Health. 2010;13(1):28–33. .
- Jo J-S, Kim Y-M, Paek KW, et al. Factors contributing to increases in prescription drug expenditures borne by national health insurance in South Korea. Yonsei Med J. 2016;57(4):1016–1021. .
- Banzi R, Gerardi C, Bertele’ V, et al. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med. 2015;26:572–584.
- Aggarwal A, Fojo T, Chamberlain C, et al. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS cancer drugs fund. Ann Oncol. 2017;28:1738–1750.
- Vivot A, Jacot J, Zeitoun J-D, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015. Ann Oncol. 2017;28:1111–1116.